Description
Sermorelin | GHRH(1-29) Analogue — Research Grade
Sermorelin (GHRH 1-29 NH2) consists of the first 29 amino acids of endogenous growth hormone-releasing hormone and represents the shortest fully active fragment of GHRH. It has been extensively characterised in both preclinical and clinical research contexts.
Mechanism of Action
- GHRH receptor agonism — binds the pituitary GHRH receptor, stimulating GH synthesis and secretion
- Physiological GH pulsatility — preserves the natural nocturnal GH pulse pattern in deficiency models
- Feedback-regulated — subject to normal somatostatin-mediated negative feedback, unlike direct GH administration
Research Areas
Sermorelin has been studied in childhood GH deficiency (FDA-approved diagnostic use), adult GH deficiency, body composition, sleep architecture, and aging research. It remains a benchmark compound in GHRH biology.
For Research Use Only. Rainbow Peptide supplies Sermorelin exclusively for in vitro and laboratory research purposes. Not for human or veterinary use.
Dr. E. Whitfield –
Sermorelin is our benchmark GHRH analogue. Rainbow Peptide’s lot passed our full QC panel including purity (>98.5%), endotoxin, and bioactivity testing. The COA was the most detailed we’ve received from any supplier.
A. Johansson –
Second order of Sermorelin. Quality has been consistent. Our in vitro GH release assay showed a dose-response curve that tracks the published literature exactly. COA confirmed molecular weight by mass spec.
P. Osei –
Sermorelin dissolved cleanly and performed well in our model. Purity verified at 98.3%. Packaging was appropriate for temperature-sensitive peptides. Fast delivery and good documentation.